Developer of enzymatic DNA technologies designed to enable genetic medicines including viral vector production, mRNA and
Developer of enzymatic DNA technologies designed to enable genetic medicines including viral vector production, mRNA and DNA based therapies and vaccines.
Discovery Tools (Healthcare)📍 Hampton, United KingdomFounded 2007
Current Valuation
$704.39M
as of 2021-Q3
PRIVATE
QL Price
$704.39M
0% vs last round
QuantLogix's current estimate for Touchlight, published 2026-09-27 — in line with the last disclosed round of $704.39M (2021-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$704.39M
2021-Q3
weight 0.03
How this price has held up
No round has priced for Touchlight since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Touchlight, 2026-09-27 (d1f598bcd36651cb).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Touchlight going public?
No. Touchlight is private and has not filed to go public. There is no S-1 on file.
What is Touchlight's valuation in 2026?
Touchlight is valued at $704.39M as of 2021-Q3, set by its Later Stage VC ($126.67M, Sep 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Touchlight filed an S-1?
No public S-1 is on file for Touchlight.
How much has Touchlight raised?
Touchlight has raised $198.91M in total, most recently a Later Stage VC of $126.67M in Sep 2021.
Is Touchlight publicly traded — can you buy Touchlight stock?
No. Touchlight is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Touchlight on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2007
HQ
Hampton, United Kingdom
Employees
177
Total Raised
$198.91M
Last Round
Later Stage VC — $126.67M (Sep 2021)
IPO Status
private
Fundraising Status
Later Stage VC · $126.67M · 5y ago
privateTotal raised $198.91M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Later Stage VC
$126.67M
Sep 2021
—
$704.39M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Touchlight — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
-7% vs 2026-08
Open roles
13
via careers page
Product-build share
62%
engineering, research, product, design
Trajectory
steady
product-led hiring — 62% of open roles build product; the rest are go-to-market and G&A.
Counted from Touchlight's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
MedicalHealth CareBiotechnologyBiopharma
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q3. Refreshed quarterly.